Oral anticoagulation (apixaban) to prevent early liver disease worsening
| ISRCTN | ISRCTN11391276 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11391276 |
| Integrated Research Application System (IRAS) | 1013519 |
| Central Portfolio Management System (CPMS) | 59179 |
| Sponsor's protocol code number | 167365 |
| Sponsor | University College London |
| Funder | National Institute for Health and Care Research |
- Submission date
- 04/06/2026
- Registration date
- 09/07/2026
- Last edited
- 05/08/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Digestive System
Plain English summary of protocol
Background and study aims
Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives. Apixaban is already commonly used to prevent or treat blood clots and is known to be safe for those with cirrhosis.
In the early stages of cirrhosis, most people have no symptoms and lead normal lives; this is called “compensated” cirrhosis. However, when the liver stops working properly, they develop “decompensated” cirrhosis, which causes yellow skin, confusion, vomiting of blood and painful fluid build-up. This is serious, and people are extremely unwell with a poor quality of life, often need to go to the hospital and on average only live for 2 more years.
The APEACH trial will investigate whether giving compensated cirrhosis patients Apixaban will help stop them from developing decompensated cirrhosis and stay in good health for longer.
Previous research studies suggest that taking blood-thinning drugs is safe and helpful for cirrhosis. However, these did not have enough participants to be confident enough in the results to recommend use in everyday clinical care. The APEACH trial will include enough participants to make it clear whether Apixaban is helpful or not.
Who can participate?
Adult patients with cirrhosis due to alcohol will be recruited from about 55 hospitals.
What does the study involve?
Participants will be randomly allocated to receive Apixaban or an identical-looking placebo. Neither patients nor doctors will know which is which in a double-blind trial. Participants will take the tablets for a minimum of 12 months up to 4 years, and will be followed up every 6 months in line with standard liver clinic appointments. They will be assessed for decompensated cirrhosis and unwanted side effects.
To minimise the burden on participants, additional trial-specific visits have been minimised to 2 telephone calls and a final visit. Follow-up visits should be arranged to coincide with standard of care appointments. All imaging and blood tests are part of the standard of care, and the only additional test will be pregnancy testing for participants of childbearing potential (estimated at 15% of participants). Should participants need to attend their trial location for an additional trial-specific visit, there will be reimbursement for patient travel.
What are the possible benefits and risks of participating?
Anticoagulation has been shown to be safe in compensated cirrhosis patients with a platelet count >50x10/L, and this has been incorporated into the exclusion criteria for the trial.
The main risk for participants is the increased risk of bleeding associated with anticoagulant use. Participants will be informed that they will potentially experience bruising or nuisance bleeding more than usual and be given advice on managing this. Trial treatment will be stopped if the participant is hospitalised during participation, and local protocol should be followed if participants require surgical or dental treatments. Participants will be given an APEACH safety card with contact information of their study team and out-of-hours advice. The safety of participants will be monitored at 6-monthly follow-up visits and telephone calls at months 1 and 3 following randomisation.
Where is the study run from?
University College London, UK.
When is the study starting and how long is it expected to run for?
June 2026 to November 2030.
Who is funding the study?
National Institute for Health and Care Research, UK.
Who is the main contact?
cctu.apeach@ucl.ac.uk
Contact information
Scientific, Public
Comprehensive Clinical Trials Unit (CCTU) at University College London (UCL)
90 High Holborn 2nd Floor
London
WC1V 6LJ
United Kingdom
| Phone | +44 0207 6704748 |
|---|---|
| cctu.apeach@ucl.ac.uk |
Principal investigator
Upper 3rd Floor, Division of Medicine, Royal Free Campus, Rowland Hill Street
London
NW3 2PF
United Kingdom
| a.o'brien@ucl.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | Parallel |
| Purpose | Prophylaxis |
| Scientific title | APEACH: Apixaban to Prevent dEcompensation of eArly liver CirrHosis trial |
| Study acronym | APEACH |
| Study objectives | APEACH will determine if apixaban reduces decompensation events in alcohol related, and metabolic-dysfunction and alcohol-associated liver disease, Childs A cirrhotic liver disease and portal hypertension. To provide safety data on use of anticoagulants in this population, including incidents of major and non-major bleeding events. |
| Ethics approval(s) |
Submitted 04/06/2026, To be confirmed (-, -, -, United Kingdom; -; -), ref: 26/YH/0102 |
| Health condition(s) or problem(s) studied | Liver cirrhosis secondary to alcohol, with or without associated metabolic risk factors, i.e. Alcohol Related Liver Disease (ARLD) or metabolic dysfunction-associated steatotic liver disease, where there has been a significant history of alcohol consumption (MetALD) |
| Intervention | 1. Apixaban 2.5mg film-coated tablets (licenced in the UK and/or approved country) 2. Placebo to match film-coated tablets (same visual appearance, no active ingredients). Participants will be instructed to take one tablet of 2.5mg / matched placebo twice a day (morning and evening). The treatment period will be for a minimum of 12 months for the final randomised participant, and a maximum of 49 months for the first randomised participant. Medication can be taken with or without food. |
| Intervention type | Drug |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Apixaban [Apixaban] |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 30/11/2030 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 110 Years |
| Sex | All |
| Target sample size at registration | 1142 |
| Key inclusion criteria | 1. Liver cirrhosis secondary to alcohol, with or without associated metabolic risk factors, i.e. Alcohol related liver disease (ARLD) or metabolic dysfunction-associated steatotic liver disease, where there has been a significant history of alcohol consumption (MetALD) 2. Cirrhosis will be based on histology, or clear radiological evidence, e.g. nodular or heterogeneous liver or non-invasive testing (e.g. Fibroscan®, or Enhanced Liver Fibrosis (ELF) test 3. Childs A Cirrhosis (Participants with a previous episode of decompensated cirrhosis who have now recompensated can be included) 4. Participants with no hepatic encephalopathy or low-grade hepatic encephalopathy (Grade 0 or 1) taking lactulose and/or rifaximin 5. Aged ≥18 years 6. Clinical evidence of portal hypertension, defined as any 1 of: 6.1. Evidence of abdominal collateral circulation, recanalised umbilical vein or varices on imaging 6.2. Asymptomatic ascites (trace only) seen around the liver on imaging in patients who are not taking diuretics 6.3. Liver stiffness measurement >20kPa on FibroScan®/ Vibration-Controlled Transient Elastography (VCTE) (where BMI <35) 6.4. Presence of Gastro-oesophageal varices at endoscopy 6.5. Hepatic venous pressure gradient ≥ 10mmHg Or Platelet count < 150,000 µL AND any 1 of: 6.6. Spleen size >13 cm in length 6.7. Liver stiffness measurement >20kPa on FibroScan®/VCTE (where BMI >35) 6.8. Presence of portal hypertensive gastropathy at endoscopy |
| Key exclusion criteria | 1. Evidence of decompensation (e.g. ascites requiring treatment other than a thin rim around the liver on imaging). (Evidence of decompensation as follows: Grade 2 or 3 Ascites, Grade 2 – 4 Hepatic Encephalopathy, Variceal Haemorrhage). 2. Causes for cirrhosis other than alcohol, including those with MASLD who have never drunk alcohol above government recommended levels (14 units/week) 3. Pre-existing splanchnic vein thrombosis (portal, splenic, mesenteric, and hepatic veins) 4. Use of (and need for) anticoagulation or dual antiplatelet therapy or clopidogrel 5. Platelets <50x109/L1 at screening 6. Moderate-severe renal impairment defined as eGFR <30ml/min at screening 7. Recent variceal bleed or untreated large varices 8. Malignancy in the last 2 years, if unlikely to survive trial because of comorbidity in the location, according to the PI’s opinion 9. Hepatocellular carcinoma 10. Severe cardiac failure or Chronic Obstructive Pulmonary Disease (COPD) 11. Pregnancy 12. INR >1.7 (after vitamin K correction) at screening 13. Previous hypersensitivity reaction to apixaban |
| Date of first enrolment | 30/06/2026 |
| Date of final enrolment | 30/04/2029 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
-
-
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
05/08/2026: Internal review.
09/07/2026: ISRCTN received notification of combined HRA/MHRA approval for this trial on 09/07/2026.
04/06/2026: Study's existence confirmed by Health Research Authority (HRA) (UK).